Skip to content
結果符合項高風險因素
您可能是肉毒高風險族群
施打肉毒桿菌素時請諮詢醫師，立即改純淨零雜質產品
結果符合2項高風險因素
您可能是肉毒高風險族群
施打肉毒桿菌素時請諮詢醫師，
立即改純淨零雜質產品
當我們接受含有雜質的肉毒桿菌素
有可能誘發身體的免疫系統，產生抗藥性
抗藥性導致療效下降甚至完全無效
如果你發現治療效果逐漸減弱，這可能是因為你對肉毒稈菌毒素產生了抗藥性。
這是長期接受不純淨的肉毒桿菌素的一個副作用
Xeomin 天使肉毒原廠認證診所
天使肉毒正式仿單名稱為淨優明凍晶注射劑，衛部菌疫輸字第000994號
- Data on file, Merz pharmaceutical GmbH, July 2021.
- Prager W, et al. Clin Interv Aging. 2013;8:449-56.
- Park JY, et al. Plast Reconstr Surg Glob Open. 2020;8(1):e2627
- Kane MA, et al. Dermatol Surg 2015;41(11):1310–1319.
- 1XEOMIN Product Information February 2019.
- 1Kerscher M, et al. Dermatol Surg. 2015;41:1149-1157.
- Saybel A, et al. J Drugs Dermatol 2015;14(11):1291–1296.
- Data on File. Merz Pharmaceuticals GmbH 2020. 15.
- Kerscher M, et al. J Drugs Dermatol 2019; 18(1):52–57
- Rappl T, Parvizi D, Friedl H, et al. Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clin Cosmet Investig Dermatol. 2013;6:211-219. Published 2013 Sep 24.
doi:10.2147/CCID.S41537
- Ho et al. Toxins. 2023; 15(7):456. A 2021.
- Carr WW, Jain N, Sublett JW. Immunogenicity of botulinum toxin formulations: potential therapeutic implications. Adv Ther. 2021;38(10):5046-5064.
- XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2023
- Walter U, Mühlenhoff C, Benecke R, et al. Frequency and risk factors of antibody-induced secondary failure of botulinum toxin therapy. Neurology. 2020;94(20):e2109-e2120.
